SOLVAY SA (SOLB.BR)       101.175  +3.31 (+3.39%)

101.175  +3.31 (+3.39%)

BE0003470755 - Common Stock


Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to SOLB. SOLB was compared to 31 industry peers in the Chemicals industry. SOLB has a bad profitability rating. Also its financial health evaluation is rather negative. A decent growth rate in combination with a cheap valuation! Better keep an eye on SOLB.




Profitability

Profitability Rating

3

SOLB's Profit Margin of 11.51% is amongst the best of the industry. SOLB does better than the industry average Profit Margin of 9.22%.
The Piotroski-F score of SOLB is 5.00. This is a neutral score and indicates average health and profitability for SOLB.

SOLB has a Return On Assets of 7.35%. This is below the industry average of 8.84%.
SOLB's Return On Equity of 15.78% is worse than the rest of the industry. The industry average Return On Equity is 17.73%.
VS Industry

ROA (7.35%) VS Industry: 40% outperformed.

2.22
19.77

ROE (15.78%) VS Industry: 40% outperformed.

4.93
36.57

Profit Margin (11.51%) VS Industry: 61% outperformed.

2.24
28.31

Valuation

Valuation Rating

8

The Price/Earnings Ratio is 6.58, which indicates a rather cheap valuation of SOLB.
SOLB's Price/Earning Ratio is a bit cheaper than the industry average which is at 10.80.
The Forward Price/Earnings Ratio of 8.30 indicates a rather cheap valuation of SOLB.
The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

With a price book ratio of 0.93, SOLB is valued rather cheaply.
Compared to an average industry price book ratio of 1.84, SOLB is valued rather cheaply
Compared to an average industry Enterprise Value to EBITDA ratio of 6.82, SOLB is valued rather cheaply
VS Industry

Price/Earnings (6.58) VS Industry: 68% outperformed.

48.09
1.72

Price/Book (0.93) VS Industry: 79% outperformed.

15.59
0.29

Enterprise Value/ EBITDA (3.97) VS Industry: 80% outperformed.

17.81
1.69

Growth

Growth Rating

6

SOLB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.67%, which is quite impressive.
The Revenue has grown by 46.01% in the past year. This is a very strong growth!
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
Measured over the past 5 years, SOLB shows a small growth in Earnings Per Share. The EPS has been growing by 4.23% on average per year.

SOLB is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 3.62% yearly.
The EPS growth is stable: in the next 5 years the growth will be about the same than in the last 5 years.
SOLB shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 2.62% yearly.
SOLB is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 9.05% yearly.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS4.23% 1.15% 79.67% 59.77% 10.22% 7.62% 3.62%
Revenue2.62% 0.4% 46.01% 32.68% 14.7% 10.41% 9.05%

Health

Health Rating

3

When comparing the Debt to Equity Ratio of 0.23 to an average industry Debt to Equity of 0.35, SOLB is way less dependent on financing that its industry peers.
SOLB has a Current Ratio of 1.33. This is a normal value and indicates that SOLB is financially healthy and should not expect problems in meeting its short term obligations.
SOLB has a Quick Ratio comparable to the industry average, which is at 1.05.
SOLB has an Altman-Z score of 1.92. This is not the best score and indicates that SOLB is in the grey zone with still only limited risk for bankruptcy at the moment.

SOLB has a Piotroski-F score of 5.00. This indicates an average health and profitability for SOLB.
Compared to an average industry Current Ratio of 1.85, SOLB is worse placed to pay its short term obligations than its industry peers.
A Quick Ratio of 1.00 indicates that SOLB may have some problems paying its short term obligations.
Compared to an average industry Altman-Z score of 3.03, SOLB is in worse financial state than most of its industry peers. 83% of its industry peers have a better Altman-Z score.
VS Industry

Debt/Equity (0.23) VS Industry: 65% outperformed.

1.10
0.00

Quick Ratio (1) VS Industry: 41% outperformed.

0.55
8.56

Current Ratio (1.33) VS Industry: 24% outperformed.

0.72
8.56

Altman-Z (1.92) VS Industry: 17% outperformed.

-2.72
7.78

Dividend

Dividend Rating

5

The dividend of SOLB is growing, but earnings are growing more, so the dividend growth is sustainable.
22.51% of the earnings are spent on dividend by SOLB. This is a low number and sustainable payout ratio.
SOLB has a Yearly Dividend Yield of 2.61%.

Compared to an average industry Dividend Yield of 2.82, SOLB has a dividend in line with its industry peers.
SOLB's Dividend Yield is comparable with the S&P500 average which is at 2.55.
VS Industry

Dividend Yield (2.61%) VS Industry: 42% outperformed.

0.95
22.31

SOLVAY SA101.175

EBR:SOLB (3/21/2023, 12:55:04 PM)+3.31 (+3.39%)

Chartmill FA Rating
GICS Sector Materials
GICS IndustryGroup Materials
GICS Industry Chemicals
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Inst Owners N/A Inst Owner Change N/A
Ins Owners N/A Ins Owner Change N/A
Market Cap 10.49B Analysts 71.67
Price Target 118.44 (17.06%)

Dividend
Industry RankSector Rank
Dividend Yield 2.61%
Dividend Growth(5Y) 0.88% DP 22.51%
Div Incr Years 1 Div Non Decr Years 3
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 32.96%
Min EPS beat(2) 22.68% Max EPS beat(2) 43.24%
EPS beat(4) 4 Avg EPS beat(4) 38.48%
Min EPS beat(4) 22.68% Max EPS beat(4) 44.95%
Revenue beat(2) 2 Avg Revenue beat(2) 25.65%
Min Revenue beat(2) 25.46% Max Revenue beat(2) 25.84%
Revenue beat(4) 4 Avg Revenue beat(4) 25.72%
Min Revenue beat(4) 22.78% Max Revenue beat(4) 28.81%
PT rev (1m) 2.81% PT rev (3m) 6.26%
EPS NQ rev (1m) 23.84% EPS NQ rev (3m) 26.72%
EPS NY rev (1m) 3.02% EPS NY rev (3m) 3.02%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) -0.82%
Revenue NY rev (1m) -2.61% Revenue NY rev (3m) -2.61%

Valuation
Industry RankSector Rank
PE 6.58
Fwd PE 8.3
P/S 0.68
P/FCF 10.51
P/OCF 5.91
P/B 0.93
P/tB 1.95
EV/EBITDA 3.97
EPS(TTM) 15.38 EY 15.2%
EPS(NY) 12.2 Fwd EY 12.05%
FCF(TTM) 9.63 FCFY 9.52%
OCF(TTM) 17.13 OCFY 16.93%
SpS 149 BVpS 108.68
TBVpS 51.99 PEG (NY) 0.11
PEG (5Y) 1.55

Profitability
Industry RankSector Rank
ROA 7.35%
ROE 15.78%
ROIC 12.12%
ROICexc 12.83%
ROICexgc 20.2%
OM 14.88%
PM 11.51%
GM 24.4%
ROICexgc(3y) 12.01% ROICexcg growth 3Y 5.02%
ROICexcg growth 5Y 7.68% ROICexc(3y) 7.01%
ROICexc growth 3Y 9.41% ROICexc growth 5Y 12.02%
OM growth 3Y 1.12% OM growth 5Y 2.97%
PM growth 3Y 4.04% PM growth 5Y 4.31%
GM growth 3Y -1.6% GM growth 5Y -1.92%
F-Score 5 Asset Turnover 0.64

Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 3.4
Debt/EBITDA 1.07
Cap/Depr 89%
Profit Quality 56.16%
Current Ratio 1.33
Quick Ratio 1
Altman-Z 1.92
F-Score 5 WACC 7.92%
ROIC/WACC 2.55 Cap/Depr(3y) 47.34%
Cap/Depr(5y) 60.32% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 79.67% EPS 3Y 1.15%
EPS 5Y 4.23% EPS growth Q2Q 85.55%
EPS Next Y 59.77% EPS Next 2Y 10.22%
EPS Next 3Y 7.62% EPS Next 5Y 3.62%
Revenue growth 1Y 46.01% Revenue growth 3Y 0.4%
Revenue growth 5Y 2.62% Revenue growth Q2Q 53.98%
Revenue Next Year 32.68% Revenue Next 2Y 14.7%
Revenue Next 3Y 10.41% Revenue Next 5Y 9.05%
EBIT growth 1Y 92.46% EBIT growth 3Y 1.52%
EBIT growth 5Y 5.67% EBIT Next Year 120.92%
EBIT Next 3Y 23.37% EBIT Next 5Y 11.15%
FCF growth 1Y 29.61% FCF growth 3Y -0.91%
FCF growth 5Y 1.35% OCF growth 1Y 26.15%
OCF growth 3Y -4.48% OCF growth 5Y -3.46%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext